Affordable Access

Publisher Website

Increased levels of transforming growth factor-β1 in essential hypertension

Authors
Journal
American Journal of Hypertension
0895-7061
Publisher
Oxford University Press
Publication Date
Volume
15
Issue
3
Identifiers
DOI: 10.1016/s0895-7061(01)02327-5
Keywords
  • Brief Communication
Disciplines
  • Medicine

Abstract

Abstract Background Transforming growth factor-β (TGF-β) is a multifunctional cytokine that has been linked to vascular remodeling processes, myocardial hypertrophy, and renal fibrosis. Recently a correlation between serum levels of TGF-β1 and blood pressure (BP) levels in patients with end-stage renal disease was shown. In addition, it is not clear whether TGF-β1 is a causative factor in the pathogenesis of essential hypertension and associated with hypertensive target organ damage (TOD). Methods Using a TGF-β1-specific sandwich ELISA, we compared plasma levels of active and total TGF-β1 of 30 normotensive persons and 85 patients with essential hypertension with and without TOD, as measured by microalbuminuria or left ventricular hypertrophy. Results Active and total TGF-β1 levels were significantly higher in plasma of patients with essential hypertension than in normotensive controls ( P < .05 and P < .01, respectively). However, neither active nor total TGF-β1 correlated with systolic or diastolic BP (R 2 < 0.14 for all parameters). Levels of active and total TGF-β1 were significantly higher in hypertensive patients with than without TOD ( P < .05). Conclusions Active and latent TGF-β1 levels are markedly increased in plasma of hypertensive patients. We assume that TGF-β1 contributes substantially to the development of TOD in essential hypertension, independent of BP levels.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments